Cutting‐Edge Therapy and Immune Escape Mechanisms in EBV‐Associated Tumors
Medicinal Research Reviews · 2025-07 · 45 (4) · 1184-1210
DOI: 10.1002/med.22104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 12.03.2025. Verfasst von Jie Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Institute of Oncology, The School of Basic Medical Sciences & Diagnostic Pathology Center, Fujian Medical University, Fuz…. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Neoplasms, Epstein-Barr Virus Infections, Tumor Escape. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 155 Literaturangaben. Gefördert von: This work was supported partially by grants from the National Natural Science Foundation of China (82303069, 52102276, and 82303126), the Natural Science Found….
Abstract (Originalsprache)
Epstein–Barr virus (EBV), the first identified human tumor virus, significantly influences the immune microenvironment of associated cancers. EBV‐induced expression of viral antigens by tumor cells triggers immune recognition and elicits a pro‐inflammatory response. While mild inflammation may help eliminate malignant cells, intense inflammation can accelerate tumor progression. Moreover, EBV can establish lifelong latency in human hosts, characterized by low immunogenicity of its proteins and noncoding RNAs. This enables tumor cells to evade immune detection and impair immune cell function, disrupting immune homeostasis. Consequently, EBV‐associated malignancies pose a considerable public health challenge globally, often complicating the prognosis of cancer patients under conventional treatment. With deeper research into the oncogenic expressions and mechanisms of EBV, novel targeted therapies against EBV are gaining prominence. This review discusses recent advancements in understanding how EBV helps tumor cells evade immune surveillance and induce immune dysfunction. It also examines the clinical potential of targeting EBV‐associated tumors, providing fresh perspectives on the mechanisms and therapeutic strategies for these cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Institute of Oncology, The School of Basic Medical Sciences & Diagnostic Pathology Center, Fujian Medical University, Fuzhou, China.
- Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, C…
- Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medicine Sciences, Central South University, Changsha, China.
- The Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, School of Medicine, Hunan Normal University; The Engineering Research Center of Reproduction and Translational Medicine of Hunan Province, Cha…
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
- Department of Forensic Science, School of Basic Medical Science, Central South University, Changsha, China.
ORCID-Profile: Jun Long
Förderung
- This work was supported partially by grants from the National Natural Science Foundation of China (82303069, 52102276, and 82303126), the Natural Science Found…
Zitieren
APA
Wang, J., Wang, R., Wang, M., Ge, J., Wang, Y., Li, Y., Chen, C., He, J., Zheng, B., Xu, M., Jiang, X., Liu, Y., Chen, M., & Long, J. (2025). Cutting‐Edge Therapy and Immune Escape Mechanisms in EBV‐Associated Tumors. Medicinal Research Reviews, 45(4), 1184-1210. https://doi.org/10.1002/med.22104
Vancouver
Wang J, Wang R, Wang M, Ge J, Wang Y, Li Y, et al. Cutting‐Edge Therapy and Immune Escape Mechanisms in EBV‐Associated Tumors. Medicinal Research Reviews. 2025;45(4):1184-1210. doi:10.1002/med.22104
BibTeX
@article{Wang2025,
author = {Wang, Jie and Wang, Rong and Wang, Meifeng and Ge, Junshang and Wang, Yian and Li, Yanhan and Chen, Changan and He, Jiale and Zheng, Boshu and Xu, Meifang and Jiang, Xianjie and Liu, Yuhang and Chen, Mingfen and Long, Jun},
title = {Cutting‐Edge Therapy and Immune Escape Mechanisms in EBV‐Associated Tumors},
journal = {Medicinal Research Reviews},
year = {2025},
volume = {45},
number = {4},
pages = {1184--1210},
doi = {10.1002/med.22104}
}
EUVIMED